CDC recommends avoiding e-cigarettes that contain THC – Financial Times

US health officials retreated from a previous warning about e-cigarette use, instead recommending that people not use THC-containing e-cigarette or vaping products.

The Centers for Disease Control and Prevention recommended that people not use e-cigarette, or vaping, products that contain tetrahydrocannabinol, the psychoactive component in cannabis, “particularly from informal sources like friends, family, or in-person or online dealers”.

The CDC found that “82% of hospitalised patients with data on substance use reported using THC-containing products; 33% reported exclusive use of THC-containing products”. It also said vitamin E acetate, an oil chemical used to dilute THC, “is strongly linked” to the lung disease (EVALI) associated with vaping.

In September, the CDC had cautioned against using e-cigarette products as it investigated vaping-related lung disease, saying people “should consider” avoiding vaping altogether.

The federal agency on Friday said emergency visits related to vaping have continued to fall after surging in August last year and peaking the following month.

The weekly emergency department visit rate peaked at 116 per million in September 2019 and fell to about 35 per million earlier this month. The agency attributed the decline to increased public awareness, removal of vitamin E acetate from certain products and law enforcement actions related to certain products.

The CDC also maintained that “adults who do not currently use tobacco products should not start using e-cigarette, or vaping, products”.

The growing e-cigarette market has come under scrutiny as regulators probe various illnesses and use of the devices among young people.

The CDC said 60 deaths have been confirmed in 27 states and the District of Columbia.

Utah’s next marijuana bill could create an expungement option for past medical cannabis use – Salt Lake Tribune

A forthcoming medical cannabis bill will contain an expungement provision for patients prosecuted in the past for possessing the substance to treat their ailments.

The anticipated legislation will likely suggest dozens of other tweaks to the state’s medical cannabis law in the months before the full program is slated to go live. The bill is in drafting phases, and elements are still in flux, but advocate Connor Boyack said he believes it will create a more patient-centered system for delivering cannabis treatments.

“We think this positions us well to continue to improve the program,” said Boyack, president of the libertarian Libertas Institute.

The expungement option will be a key piece of the proposal, along with the deletion of an unpopular requirement that marijuana flower must be sold in a blister pack. The updates will likely call for selling cannabis buds in glass jars, although there will still be an effort to ensure consistency in dosing, Boyack said.

„Blister packs were something we had to get away from for industry and for patients,” said Desiree Hennessy, executive director of the Utah Patients Coalition. „It was just too costly.”

Senate Majority Leader Evan Vickers, R-Cedar City, will be sponsoring the legislation with an assist from Rep. Brad Daw, who predicted that officials will continue refining the state’s cannabis program for years to come.

„The overall goal is the same: To get legitimate, high-quality medicine to those who have a legitimate need,” Daw, R-Orem, said.

(Rick Bowmer | AP file photo) Brad Daw, left, R-Orem, speaks with Brian King, D-Salt Lake City, on the floor of the Utah House of Representatives, Sept. 16, 2019, in Salt Lake City. Utah lawmakers are expected to consider changes to the state’s medical marijuana law, an issue that has faced fierce criticism from people on both sides of the debate.

Boyack said the expungement provision will likely be available to people with a qualifying condition who used cannabis in one of the approved medical forms; the state’s law restricts the amount of marijuana a patient can possess at any one time and prohibits smoking the substance.

The upcoming bill could specify that if someone in this situation claims he or she was only using CBD, the government couldn’t impose sanctions without offering additional evidence of marijuana possession, he said.

Boyack said the legislation might also address methods of testing for driving while impaired by marijuana.

„The cannabis metabolite can linger up to a month,” he said. „This presents a huge problem, because those people can be criminalized, even though they’re not impaired, even though they legally used the cannabis weeks prior.”

Boyack said the proposal could narrow the testing to focus on certain active metabolites that don’t linger for as long in a person’s system, a change that would probably apply to medical and recreational users alike.

„We want to be careful about that because of the whole idea of Dr. Feelgood,” Daw said.

The bill will be considered in the Legislature’s upcoming 45-day session, which will begin Jan. 27.

Ambient Vaporizer Market: Capture Most Advanced and Extencive Study Report With Top Key Players: Linde Engineering, Cryolor, Triumph, Cryoquip – Dagoretti News – Dagoretti News

(Jan 2020) WMR published report on Ambient Vaporizer Market 2027: Delivering key insights and providing a competitive advantage to clients through a detailed report. Ambient Vaporizer Industry Size, Market Share Value, Competitors Research, Industry Outlook as well Analysis covers various factors like Regional Analysis, Ambient Vaporizer Type, Applications, etc.

The intelligence in Ambient Vaporizer Market report by Worldwide Market Report includes investigations based on the current scenarios, historical records, and future predictions. Conclude an accurate data of various aspects. It presents the 360° overview of the competitive landscape of the industries. Thus, helping the companies to understand the threats and challenges in front of the businesses.

Downlaod PDF Brochure with Full Analysis of Key Players

Following Key Players are Analysed in this Report:

  • Linde Engineering
  • Cryolor
  • Triumph
  • Cryoquip
  • Cryonorm
  • Fuping Gas Equipment

(*other Player can be added on demand)

Regional Insights of Ambient Vaporizer Market

1. Asia-Pacific has recorded impressive growth in Ambient Vaporizer Industry, both in volume and Ambient Vaporizer and is expected to highest growth rate during the forecast period owing to increasing adoption of automation by manufacturing industries and adoption of industrial Ambient Vaporizer throughout the region.

2. Countries such as China, Japan, Thailand, and South Korea are manufacturing both commercial and industrial Ambient Vaporizer in high volume. The adoption rate of Ambient Vaporizer in China and India is very high, owing to the massive deployment in the manufacturing sector.

3. For instance, The National Authorities are planing to make the amendments in laws to boost in the economy with change in latest trends, and recently tying up with other worldwide nations on it as well.

4. The Ambient Vaporizer market research report outlines the Regional key trends, market sizing and forecasting for various emerging sub-segments of market.

Ambient Vaporizer Report Covers:

  • Executive Summary: Market Overview, Scope of Statistics of Ambient Vaporizer Market
  • Market Segmentation: Market by Type, Market By Application
  • Prominent Players:
    • Organization Information,
    • Product and Services,
    • Business Data,
    • Recent Development
  • Geographical segmentation: Regional Production, Regional Demand, Regional Trade
  • Price Overview: Cost by Manufacturers, Price by Application, Price by Type

At the end, Ambient Vaporizer Market reports deliver insight and expert analysis into key trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Ambient Vaporizer Market reports provides all data with easily digestible information to guide every businessman’s future innovation and move business forward.

Customization Service of the Report:
Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you to get a report that suits your necessities.

Canopy Growth Delays THC Beverage Launch Date – Benzinga

Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) said Friday it has made significant progress toward scaling the production process for its cannabis beverages, but it is extending out the date by which the beverages will reach the market. 

The company had previously said the products would reach the market in early January. 

The company obtained the license for its beverage facility in late November, and said it has been working on bringing the production process to commercial scale. 

Canopy is enthusiastic about the underlying beverage science and its ability to scale production and introduce high-quality cannabis beverages to the market, the company said in a statement. 

Benzinga’s Cannabis Capital Conference returns to Miami Feb. 24-25 with North America’s largest B2B cannabis gathering, bringing together capital, cannabis executives, thought leaders and more!

Nevertheless, the scaling process is still ongoing. 

„Canopy has had seven weeks to work with THC in the brand-new beverage facility to scale processes and IP it has developed in the R&D environment,” CEO David Klein said in a statement.

„In order to deliver products that meet our customer’s high standards we are electing to revise the launch date while we work through the final details.”

Canopy did not disclose a date by which the beverages will reach the market. The company said an update will be issued alongisde its third-quarter results. 

Canopy Growth shares were trading 2.84% higher at $24.99 at the time of publication Friday. 

Related Links:

Canopy Growth, Fire & Flower Among Companies Bidding To Operate New Brunswick’s Cannabis Sales

The Week In Cannabis: New York, Mississippi, Illinois, Mexico, High Times And More

Photo courtesy of Canopy Growth. 

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Analyst: Most Canadian marijuana firms not ready for next wave of products – Marijuana Business Daily

The majority of Canadian cannabis companies were not ready for the launch of new cannabis products such as edibles, extracts and topicals, despite having more than a year to prepare for the Cannabis 2.0 era, according to an analyst.

Only 10 companies had products available when Ontario’s only legal online store started selling the products Thursday, Mackie Research Capital wrote in a note to investors.

The Ontario Cannabis Store (OCS) sold out of edibles within hours of their initial availability, though some of the products remain available in limited quantities though the province’s approximately two dozen physical stores.

Among Mackie Research’s observations:

  • There is limited supply. Edibles products sold out, and there is limited availability for vape products.
  • The OCS is typically 20% cheaper than buying at a retail store, but there is a delivery charge for online orders.
  • Prices in the regulated sector must come down.

“Our view is that prices for both vapes and edibles are not yet competitive with the black market,” Mackie Research wrote.

For example, some edibles available through nonregulated channels currently sell for approximately 10 Canadian cents ($.08) per milligram of THC.

That compares to competing products in the regulated market that are over nine times more expensive.

The Mackie comparison also found that disposable vapes purchased through unregulated sources are significantly cheaper than legally sourced cannabis vaporizers.

Industry experts believe that derivative products – oils, vape pens, edibles and beverages – will eventually represent at least 50% of legal market demand.

“Companies that currently have products available will have a first-mover advantage, and this could result in increased brand awareness,” Greg McLeish of Mackie Research told Marijuana Business Daily.

“In an environment where you can’t brand products, this is a big advantage.”

The OCS started selling more than 70 newly regulated products online Thursday, including chocolates, cookies, soft chews, mints, teas and vapes.

Beverages were not among those products.

On Friday, market leader Canopy Growth walked back expectations that it would have cannabis beverages for sale in January.

“In order to deliver products that meet our customers’ high standards, we are electing to revise the launch date while we work through the final details,” Canopy’s new CEO, David Klein, said in a statement.

Klein took the reins of the multinational cannabis firm this week.

Canopy said its scaling process is not complete, forcing it to delay its to-market date.

The company plans to provide an update with the release of its third-quarter financial results.

The Ontario Cannabis Store is working with federally licensed companies to bring beverages to market, but the provincial wholesaler still does not have specific dates when the products will be available.

“As soon as the (licensed producers) make beverages available to us, we will rapidly move them to market,” OCS Communications Director Daffyd Roderick wrote in an emailed statement.

Canopy trades on the New York Stock Exchange as CGC and the Toronto Stock Exchange as WEED.

Matt Lamers is Marijuana Business Daily’s international editor, based near Toronto. He can be reached at [email protected].

Eaze’s struggles reflect falling VC interest in cannabis startups – TechCrunch

TechCrunch ist jetzt Teil der Verizon Media-Familie. Wir (Verizon Media) und unsere Partner benötigen Ihre Einwilligung, um auf Ihr Gerät zuzugreifen, Cookies zu setzen und Ihre Daten einschließlich Ihres Standorts zu nutzen, um mehr über Ihre Interessen zu erfahren, relevante Werbung bereitzustellen und deren Effektivität zu messen. Verizon Media stellt Ihnen zudem relevante Anzeigen auf den Produkten unserer Partner zur Verfügung. Lernen Sie hier mehr darüber

Wie Verizon Media und unsere Partner Ihnen bessere Werbung anbieten

Um Ihnen insgesamt ein besseres Nutzererlebnis zu bieten, möchten wir relevante Anzeigen bereitstellen, die für Sie nützlicher sind. Wenn Sie z. B. nach einem bestimmten Film suchen, nutzen wir Ihre Suchdaten und Ihren Standort zur Anzeige von Kinos in Ihrer Nähe. Zudem nutzen wir diese Daten, um Ihnen Werbung für ähnliche Filme zu zeigen, die Ihnen vielleicht auch gefallen könnten. Wie bei Verizon Media zeigen Ihnen unsere Partner eventuell auch Werbung, von der sie annehmen, dass sie Ihren Interessen entspricht.

Erfahren Sie mehr darüber, wie Verizon Media Daten erfasst und verwendet und wie unsere Partner Daten erfassen und verwenden.

Wählen Sie „OK“ aus, damit Verizon Media und unsere Partner Ihre Daten verwenden können, oder „Optionen verwalten“, um unsere Partner und Ihre Auswahlmöglichkeiten anzusehen. Tipp: Melden Sie sich an, um Ihre Auswahl zu speichern, damit Sie diesen Vorgang nicht auf allen Geräten einzeln durchführen müssen. Sie können Ihre Einstellungen jederzeit im Datenschutzcenter aktualisieren.

State recalls cannabis product after it fails pesticide test – KDRV

SALEM, Ore. — A cannabis product being sold at shops around the state of Oregon is being recalled after failing a test for pesticide levels, according to the Oregon Liquor Control Commission (OLCC).

The agency said that is was „issuing an immediate health and safety advisory due to the identification of potentially unsafe pesticide residue” in pre-rolled joints sold with the brand-name Winberry Farms, under the name Sweet Leaf Blend. The strain name is „Trap Star.”

Cannabis in the product was cultivated by licensed producer Ard Di and packaged for sale by DYME Distribution. It has the identification number 1A4010300022859000015892.

„The affected marijuana flower failed its pesticide test, because it exceeded the acceptable level, known as the ‚action limit,’ for the insecticide Imidacloprid,” OLCC said in a statement.

The OLCC said that it has locked down the product within its „Cannabis Tracking System” so that it won’t be distributed or sold to any further customers. 700 of the pre-rolls had already been distributed, and the OLCC said that retailers had pulled 328 packages from their shelves.

Tainted joints were sold beginning on December 17 through January 8 at nine different shops throughout Oregon, including one in Rogue River:

  • Spark, 5103 NE Fremont Street, Portland
  • Ancient Remedies, 2350 State Street, Salem
  • Puff Oregon, 47700 NW Sunset Highway, Manning
  • Rogue River Herbal PMC, 510 East Main, Suite C, Rogue River
  • The Joint, 3270 Market Street NE, Salem
  • Stoney Only Clackamas, 10289 SE Highway 212, Clackamas
  • Tsunami Marijuana LLC, 36412 Highway 26, Seaside
  • Track Town Collective, 3675 Franklin Blvd., Eugene
  • Green Room, 2521 NW 9th Street, Corvallis

Regulators said that a lab in Corvallis had failed to send samples of the product onto a second lab — a requirement — after the cannabis showed mixed results in initial tests. As a result, the OLCC didn’t find out about the issue until January 6 when an audit of the products resulted in more failed tests.

„Consumers who have these recalled products should dispose of the products or return them to the retailer where they were purchased,” the agency said.

There have been no reports of illness from using the products, but the OLCC said that health impacts from consuming that amount of pesticide is unknown.

„Short and long-term health impacts may exist depending on the specific product, duration, frequency, level of exposure, and route of exposure,” OLCC said.

European Commission falls short on WHO cannabis recommendations, experts say – Marijuana Business Daily


The European Commission’s proposal that European Union-member countries support three of the six World Health Organization (WHO) cannabis scheduling recommendations does not merit much celebration from the cannabis industry, according to international drug policy experts.

“The only good point in the draft’s common position is that the EU should support the deletion of cannabis from Schedule IV, but beyond that, there are many weaknesses and serious problems,” Martin Jelsma, drugs and democracy program director at the Netherlands-based Transnational Institute, told Marijuana Business Daily.

The European Commission’s proposal to vote as a block is meaningful because EU countries represent almost a quarter of the total votes at the March session of the United Nations Commission on Narcotic Drugs (CND).

One of the changes recommended by the WHO and supported by the European Commission is transferring THC from the 1971 convention to Schedule I of the 1961 convention.

According to the Commission, this “implies no change in the international control level.”

But Jelsma said the Commission position “reveals a worrisome lack of understanding of the UN drug control treaty system.”

The reason is that the 1971 convention requires less frequent estimates and reporting of legitimate use by member states than the 1961 treaty.

In the case of CBD, the Commission argued that “the differentiated treatment of cannabidiol compared to other cannabinoids is not justified.”

Jelsma told MJBizDaily that this “denies the outcomes of the WHO’s critical review of CBD.”

The critical review of CBD published by the WHO concluded that “there are no case reports of abuse or dependence relating to the use of pure CBD” and “no public health problems have been associated with CBD use.”

Jelsma warned that the European Commission proposal, as it stands, could have significant unintended consequences for the availability of medical cannabis in Europe.

Michael Krawitz, executive director of Veterans for Medical Cannabis Access, a Michigan-based organization that helped coordinate civil society contributions to the WHO cannabis review process, said he is disappointed the Commission is not supporting any “significant change in the control” of cannabis.

“The WHO is the authority listed by the treaty itself to make these scheduling evaluations,” he said, “and to oppose them is to disrespect the process, the evidence and those who actually rely on medicine, the patients.”

Alfredo Pascual can be reached at [email protected]
Alfredo Pascual can be reached at [email protected]

‚Dukes of Hazzard’ star says CBD helped cure wife’s stage 4 cancer – Fox Business

CBD has grown exponentially as a method of pain relief, reducing anxiety and alleviating cancer symptoms.

Continue Reading Below

Alicia Allain, wife of John Schneider, known for his role as „Bo Duke” on „The Dukes of Hazzard,” that aired on CBS from 1979 to 1985, claims CBD helped cure her of stage four HER2 negative hormone receptor-positive cancer. Allain told FOX Business’ Stuart Varney on Friday that the cancer was found on her legs, arms, rib cage and spine.

Allain said after doing research, she found certain minerals, hemp and CBD were linked to alleviating cancer symptoms. She began taking CBD orally twice a day and now credits it to ready her body to cure the cancer.

HOW CBD ‚CURED’ THIS FORMER NFL PLAYER

“It was conditioning my body to fight it,” she said. “I don’t have a genetic marker for cancer at all. So if my DNA had a break in the system, how do we get my DNA back to… normal?”

Schneider said he launched “Yee Haa” CBD oil brand “CBoD”,” an allusion to his character, to help battle the sickness. Schneider believes CBD made his wife „more receptive” to medication and dietary changes and aided in making her body „more aggressive in fighting it.”

GET FOX BUSINESS ON THE GO BY CLICKING HERE

While CBD isn’t the cure for cancer, Schneider believes it can be used as a method of getting your body “ready for battle. Within five months, Allain was cancer-free.

Schneider’s CBD oil comes in flavors including apple moonshine, in the spirit of „The Dukes of Hazzard.” He continues to motivate those who have been diagnosed with cancer to not accept defeat at first diagnosis.

“Fight it,” he said. “It’s not a battle you lost when you hear [you have cancer]. You can fight it. You must be active. You must be your own biggest fan.”

CLICK HERE TO READ MORE ON FOX BUSINESS